NuBest VITAMIN K2 Tall Protein Powder Instructions
- June 1, 2024
- NuBest
Table of Contents
NuBest VITAMIN K2 Tall Protein Powder
Product Information
- Specifications
- Product Name: Vitamin K2
- Forms: Synthetic MK-4, Natural MK-7 (MenaQ7)
- Recommended Dosage: 20mcg of Vitamin K (as MK-7)
- Benefits: Supports bone health, aids in blood clotting, helps in calcium distribution
- What is Vitamin K2?
- Vitamin K2 is an essential nutrient that plays a crucial role in bone health, blood clotting, and calcium distribution in the body. It comes in two forms – synthetic MK-4 and natural MK-7, with MK-7 being more readily absorbed.
- How to Use
- For children aged 2+ to teens, mix 20mcg of Vitamin K (as MK-7) in NuBest Tall Protein Powder with the preferred drink once daily. This formula is designed to support children’s health and body development.
- Storage
- Store the product in a cool, dry place away from direct sunlight. Keep out of reach of children.
- Precautions
- Consult a healthcare professional before starting any new supplement regimen, especially if you are pregnant, nursing, or have underlying health conditions.
FAQs
- What are the benefits of Vitamin K2?
- Vitamin K2 supports bone health by aiding in calcium distribution and plays a role in blood clotting for faster wound healing.
- Can children consume Vitamin K2?
- Yes, Vitamin K2 is safe for children aged 2 and above. However, it is recommended to follow the dosage instructions and consult a healthcare professional if needed.
- Is NuBest Tall Protein Powder suitable for picky eaters?
- Yes, NuBest Tall Protein Powder is suitable for picky eaters as it comes in two delicious flavours – Chocolate and Vanilla, making it easier for children to consume their daily nutrients.
Product Usage Instructions
Centuries ago in feudal Japan, Samurai warriors used to consume large amounts of natto – a dish made of fermented soybeans. Even today, it is consumed widely and considered as the highest food source of vitamin K2. Besides natto, Vitamin K2 can also be found in many fermented foods, such as miso and sauerkraut, as well as in animal products, including meat, butter, egg yolks, cheese, and yogurt. Historically, human diets were rich in vitamin K2, but at some point, this changed and now many people suffer from a deficiency of this vitamin. Scientific research suggests that modern Western diets are not providing sufficient amounts of vitamin K2, which is an essential nutrient. This deficiency has become a common problem among people in recent times, even though human diets were abundant in vitamin K2 in the past.
What is vitamin K2?
- Vitamin K2 is an essential nutrient required by the body throughout our lives.
- This fat-soluble vitamin helps activate calcium-binding proteins, which aid in the efficient distribution of Calcium to necessary places and contribute to bone health.
- It also plays a crucial role in blood clotting, which accelerates the healing process of wounds.
- There are two forms of Vitamin K2, synthetic MK-4, and natural MK-7.
- Natural MK-7 is more readily absorbed by the body than synthetic MK-4, as suggested by studies.
- MenaQ7 is a vegan-friendly and allergen-free form of Vitamin K2, which is known to be the most bioactive form of Vitamin K2 available in the market.
- It has been used in various clinical trials to explore the potential benefits of this little-known vitamin.
NuBest Tall Protein Powder
20mcg of Vitamin K (as Menaquinone-7 (MK-7))
- Offering a comprehensive blend of essential nutrients in one convenient formula, NuBest Tall Protein is expertly crafted to accelerate children’s health and body development, from ages 2+ to teens.
- Perfect for active kids and teens, even picky eaters, it is available in two delicious flavours – Chocolate and Vanilla.
- Whether as an instant energy boost, an on-the-go meal, or a lunchbox beverage, simply mix it with the preferred drink and grow strong with one daily shake.*
CLINICALLY PROVEN RESULTS
Study
- ‘Decreased Levels of Circulating Carboxylated Osteocalcin in Children with Low Energy Fractures:
- A Pilot Study’ Janusz Popko, Sylwia Chojnowska, Leon J. Schurgers, et al. from different departments in Poland, USA, and The Netherlands
Purpose
- The study evaluates vitamin D and K status in children with and without low-energy fractures to understand their roles in bone health.
Study details
- Group 1: 20 children (6 girls and 14 boys) aged 5 to 15 years old, with radiologically confirmed low-energy fractures
- Group 2: 19 healthy children (10 girls and 9 boys) aged 7 to 17 years old, with no fractures
- Total vitamin D (25(OH)D3 plus 25(OH)D2), Calcium, BALP (bone alkaline phosphatase), NTX (N-terminal telopeptide), and uncarboxylated (ucOC) and carboxylated osteocalcin (cOC) serum concentrations were evaluated.
- The ratio of serum uncarboxylated osteocalcin to serum carboxylated osteocalcin (UCR) was used to indicate bone vitamin K status.
Results
There were no notable statistical variances observed in the serum calcium, NTx, BALP, or total vitamin D levels between the two groups. Nevertheless, a significant difference was identified in the UCR ratio. The median UCR value in the fracture group stood at 0.471, higher than the control group’s value of 0.245 (p < 0.0001). Through logistic regression analysis, it was determined that the odds ratio for low-energy fractures associated with UCR exhibited a substantial increase, approximately 78.3 times higher.
Conclusion
A superior vitamin K status, indicated by the ucOC:cOC-UCR ratio, demonstrates a positive and statistically significant correlation with a decreased incidence of low-energy fractures.
Figure 1: Undercarboxylated and carboxylated osteocalcin in children with bone fracture and non-fracture controls. The carboxylated osteocalcin is significantly (*** p < 0.0001) decreased in children with bone fractures (left-hand figure) which is reflected by a higher UCR ratio (right-hand figure)
Study
- ‘Vitamin K Supplementation Modulates Bone Metabolism and Ultra-Structure of Ovariectomized Mice’ Letícia Batista Azevedo Rangel, Maura da Cunha, Sérgio Ragi Eis, et al. from different departments in Brazil
Purpose
- Osteoporosis is a bone disease that affects women after menopause. Vitamin K (VK) supplements during menopause may reduce bone loss and fracture risk.
- Researchers studied mineral metabolism and bone structure of mice that had their ovaries removed to understand the benefits of vitamin K on bone metabolism during menopause.
Study details
- 24 female mice, aged 6 months old
- Divided into 4 groups, including SHAM Operated MOCK Treated, SHAM Operated VK Treated, OVX MOCK Treated, and OVX VK Treated
- Duration: 90 days
Measurement
- Researchers employed various techniques, including DXA, µCTScan, and SEM, along with biomolecular methods, like ELISA and qRT-PCR, to determine the effects of chronic VK usage on bone structure and mineral metabolism in OVX mice.
- A comprehensive analysis of serum hormonal levels and other molecules linked to bone and lipid metabolism was conducted to gain insight into the effects of VK in a menopausal murine model.
Results
- VK treatment has a significant impact on Pi metabolism regardless of OVX, resulting in alterations in plasma Pi levels, urinary output, balance, and Pi content in bone. Intriguingly, VK administration also led to an increase in VLDL levels in mice independently of castration.
- VK was found to enhance compact bone mass in OVX mice, as evidenced by assessments using DXA, histomorphometry, and µCT scanning. This was accompanied by elevated levels of bone formation markers, such as osteocalcin, HYP-osteocalcin, and AP, while concurrently reducing bone resorption markers, like the urinary DPD/creatinine ratio and plasmatic TRAP.
- SEM images revealed a notable improvement in microfractures in OVX mice treated with VK compared to untreated controls.
- SHAM-operated VK Treated displayed a higher number of migrating osteoblasts and enhanced in situ secretion of AP. OVX resulted in a decrease in in situ AP secretion, which was restored by VK treatment. Additionally, VK supplementation increased mRNA expression of bone Calbindin 28KDa independent of OVX.
- Figure 1A: DXA from an average of measurements at the end-point of treatment. SHAM-operated VK-treated mice showed an increase in BMD when compared to SHAM-operated Mock-treated mice. As expected, OVX in SHAM-operated OVX mice led to a decrease in their SHAM-operated control time course of increasing which ins reversed by VK Measu treatment.
- Figure 2A: It was observed that VK treated enhances the mRNA of Cbp28k in 80% independently of OVX. It is known the influx of Ca2+ buffered by Cbp28k in osteoblast activates exocytosis of several matrix proteins, hence we evaluated secretion of AP in situ in femurs by histochemical methods.
Conclusion
- VK treatment improved bone ultrastructure in OVX mice by enhancing osteoblastic function and organic bone matrix secretion.
- Therefore, VK could be a promising treatment option for patients with osteopenia/osteoporosis.
Study
- ‘‘The effect of menaquinone-7 (vitamin K2) supplementation on osteocalcin carboxylation in healthy prepubertal children Marieke J. H. van Summeren, Leon J. Schurgers, et al. from The Netherlands
Purpose
- The study aimed to investigate the effect of 45mg of menaquinone-7 (MK-7), which is a type of vitamin K2, on the levels of undercarboxylated osteocalcin (ucOC) and carboxylated osteocalcin (cOC) in healthy prepubertal children.
Study details
- 8-week duration
- 55 healthy children, aged between 6 and 10 years, with normal (3rd to 97th percentile) height and weight
- One group receiving a placebo, the other group receiving a supplement containing 45 mg MK-7
Measurements
- Serum levels of ucOC, cOC and MK-7 were measured at baseline and after 8 weeks, together with bone markers and coagulation parameters.
- The UCR was used as an indicator of vitamin K status.
Results
- In the MK-7-supplemented group (n 28), the circulating concentration of inactive ucOC reduced and the UCR improved whereas the concentration of MK-7 increased.
- Within the placebo group, ucOC, cOC, UCR, and MK-7 did not significantly change over time.
- In both groups, bone markers and coagulation parameters remained constant over time.
Conclusion
- Modest supplementation with MK-7 increases circulating concentrations of MK-7 and osteocalcin carboxylation in healthy prepubertal children.
Figure 1: Vitamin K parameters at baseline and after 8 weeks in the placebo and vitamin K groups. Differences from baseline to follow-up in each group were examined using Wilcoxon signed-ranks tests. (a) Carboxylated osteocalcin. The differences from baseline to follow-up in the placebo and vitamin K groups were NS (P¼0·657 and P¼0·067 respectively). (b) Undercarboxylated osteocalcin. The difference from baseline to follow-up in the placebo group was NS (P¼0·228). The difference from baseline to follow-up in the vitamin K group was significant (P,0·001). (c) Undercarboxylated osteocalcin:carboxylated osteocalcin ratio (UCR). The difference from baseline to follow-up in the placebo group was NS (P¼0·451). The difference from baseline to follow-up in the vitamin K group was significant (P,0·001). (d) Serum menaquinone-7 (MK-7). The difference from baseline to follow-up in the placebo group was NS (P¼0·244). The difference from baseline to follow-up in the vitamin K group was significant (P,0·001).
Study
- ‘’The combined effect of vitamin K and calcium on bone mineral density in humans: a meta-analysis of randomized controlled trials’
- Liyou Hu, Jindou Ji, Dong Li, Jing Meng, and Bo Yu from Shandong University of Traditional Chinese Medicine, Jinan, China
Purpose
- A systematic review of randomized controlled trials assessed the combined effect of vitamin K and calcium on bone mineral density (BMD) and undercarboxylated osteocalcin (UcOC) in humans, aiming to address inconsistencies in previous research.
Study details
- 1346 patients from 10 randomized controlled trials
- The intervention duration of all studies: From 6 months to 4 years
- The included studies: 6 trials were conducted with vitamin K1 and 7 with vitamin K2
- Figure 2: Effect of the combination of vitamin K and calcium on UcOC
Results
- Vitamin K combined with calcium was associated with a higher lumbar spine BMD compared to controls. The SMD was 0.20 [95% confidence interval (CI): 0.07 to 0.32] (Fig. 1 (a) & (b)).
- Vitamin K and calcium supplementation led to a significant decrease in UcOC (SMD: – 1.71, 95% CI: – 2.45 to – 0.96) (Fig. 2).
- Subgroup analysis showed that vitamin K2 and vitamin K1 had SMDs of 0.30 (95% CI: 0.10 to 0.51) and SMDs of 0.14 (95% CI: – 0.02 to 0.29), and calcium dosages of ≤ 1000 mg/d or > 1000 mg/d had SMDs of 0.19 (95% CI: 0.05 to 0.32) and 0.26 (95% CI: – 0.04 to 0.55) (Table 1)
Conclusion
- The combination of vitamin K and calcium has a positive effect on lumbar BMD and decreases the level of UcOC.
- Figure 1 (a) Combined effect of vitamin K and calcium on lumbar bone density. (b) Sensitivity analysis of vitamin K and calcium on lumbar bone density
A recommended dose of NuBest Tall Protein provides 20 mcg of Vitamin K, allowing the diet and other supplements to bring the remaining RDI for optimal health. Furthermore, the protein powder is loaded with essential vitamins A, B, C, D & and E, Calcium, Zinc, Magnesium, and so much more nutrients, all of which contribute to healthy bone strength, energy, and overall health. GROW STRONGER FOR A BRIGHTER FUTURE